But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

For the second year in a row, Bausch + Lomb has joined with the Glaucoma Research Foundation to launch the “Faces of Glaucoma ...

PharmaEssentia is looking to expand the reach of its FDA-approved rare blood cancer treatment Besremi to another rare blood ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

Klick Health is taking a fellow life-sci-centric agency under its wing. | Klick Health is taking a fellow life-sci-centric ...

In a warning letter posted online late last month, the FDA scolded Viatris over a range of production slights at the ...

In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory ...

From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...

In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...